Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.

BACKGROUND: Type 1 insulin-like growth factor receptor (IGF-1R) mediates resistance to chemotherapy and targeted agents. This study assessed the safety, pharmacokinetics (PK), and tolerability of humanized IGF-1R antibody AVE1642 with other cancer treatments. PATIENTS: Patients with advanced solid t...

Full description

Bibliographic Details
Main Authors: Macaulay, V, Middleton, M, Protheroe, A, Tolcher, A, Dieras, V, Sessa, C, Bahleda, R, Blay, J, LoRusso, P, Mery-Mignard, D, Soria, J
Format: Journal article
Language:English
Published: 2013

Similar Items